We, therefore, tested the novel dual GLP-1/GIP receptor agonist DA5-CH that previously showed good effects in the MPTP mouse model and the 6-OHDA rat model of PD [29, 32, 40] in the transgenic A53T mouse model of PD and compared the effects with those of liraglutide. The gene discussed is GCG; the disease is Parkinson disease.